Analyzing...
Loading company...
Nothing flagged for monitoring
“Operates in Chemicals — Specialty & Commodity.”
₹383 Cr revenue.
COGS 52.0%, employees 13.8%.
“operating revenue of rupees $1,313,000,000”
“48% year on year growth and a 6% sequential increase.”
“Pharma and agro intermediates revenue ₹471cr (45% sequential, 86% YoY growth)”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 4.3%▼ | 7.6% |
| ROCE | 5.9%▼ | 10.9% |
| Net Margin | 6.8%▲ | 5.1% |
| EBITDA Margin | 16.2%▲ | 12.1% |
| Debt To Equity | 0.11x▼ | 0.20x |
| Rev Growth 3yr | -4.5%▼ | 5.9% |
| EPS Growth 3yr | -61.7%▼ | -9.4% |
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | ₹480 Cr +25.3% | ₹383 Cr -2.7% | ₹394 Cr -7.1% | ₹424 Cr -2.3% | ₹434 Cr |
| Other Income | ₹5 Cr +99.5% | ₹2 Cr -69.2% | ₹8 Cr +30.7% | ₹6 Cr -35.4% | ₹9 Cr |
| Total Income | ₹484 Cr +25.8% | ₹385 Cr -4.0% | ₹401 Cr -6.6% | ₹429 Cr -3.0% | ₹443 Cr |
| COGS | ₹226 Cr +13.6% | ₹199 Cr +14.2% | ₹174 Cr -23.0% | ₹226 Cr +16.2% | ₹195 Cr |
| ₹442 Cr +17.0% | ₹377 Cr +5.6% | ₹357 Cr -6.2% | ₹381 Cr +12.6% | ₹338 Cr | |
| Profit Before Tax | ₹42 Cr +460.1% | ₹8 Cr -82.6% | ₹44 Cr -2.7% | ₹45 Cr -57.0% | ₹104 Cr |
| ₹10 Cr +419.1% | ₹2 Cr -85.9% | ₹13 Cr ↑ Recovery | (₹0.71 Cr) ↓ Decline | ₹8 Cr | |
| Net Profit | ₹33 Cr +473.5% | ₹6 Cr -81.2% | ₹30 Cr -33.3% | ₹45 Cr -52.6% | ₹96 Cr |
| Profit (Owners) | ₹33 Cr +473.5% | ₹6 Cr -81.2% | ₹30 Cr -33.3% | ₹45 Cr -52.6% | ₹96 Cr |
| Other Comprehensive Income | ₹2 Cr +177.1% | ₹0.71 Cr | ₹0.02 Cr -96.8% | ₹0.65 Cr ↑ Recovery | (₹0.14 Cr) |
| EPS | ₹14.00 | ₹2.44 | ₹12.98 | ₹20.52 | ₹43.25 |
| Diluted Shares | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
Tatva Chintan Pharma Chem Limited has informed the Exchange about Schedule of meet
Shekhar Rasiklal Somani has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regula...
Tatva Chintan Pharma Chem Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeove...
Ajay Mansukhlal Patel has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulati...
Tatva Chintan Pharma Chem Limited has informed the Exchange about Transcript
Tatva Chintan Pharma Chem Limited has informed the Exchange about Investor Presentation
Tatva Chintan Pharma Chem Limited has informed the Exchange regarding Change in Auditors of the company.
Tatva Chintan Pharma Chem Limited has informed the Exchange that Board of Directors at its meeting held on May 16, 2026, recommended Final Dividend of Rs. 2 per equity share.
Tatva Chintan Pharma Chem Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
Tatva Chintan Pharma Chem Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Tatva Chintan Pharma Chem Limited has informed the Exchange about Schedule of meet
Tatva Chintan Pharma Chem Limited has informed the Exchange about Schedule of meet
Tatva Chintan Pharma Chem Limited has informed the Exchange regarding 'copy of the Report filed by the Promoter of the Company with SEBI under Regulation 10(7) of SEBI (Substantial Acquisition of Shar...
Tatva Chintan Pharma Chem Limited has informed the Exchange about Acquisition
Tatva Chintan Pharma Chem Limited has informed the Exchange about Schedule of meet